Sun Pharma to Acquire Checkpoint Therapeutics For ~$355M
Shots:
- Sun Pharma to acquire Checkpoint Therapeutics for ~$355M to strengthen its onco-derm innovative portfolio with Unloxcyt (cosibelimab-ipdl); closing expected in Q2’25
- As per the deal, Checkpoint stockholders will get $4.10 cash/share (~66% premium) upfront & CVR/share without interest allowing stockholders to receive additional $0.70 cash/share if Unloxcyt is approved before certain deadlines in the EU or in Germany, France, Italy, Spain or UK as per CVR agreement
- Checkpoint, Sun, & Fortress Biotech have also signed royalty agreement, granting Fortress royalties on future Unloxcyt sales during a specified term, replacing prior rights from Checkpoint’s establishment after closing
Ref: Sun Pharma | Image: Checkpoint Therapeutics
Related News:- Checkpoint Therapeutics’ Unloxcyt (Cosibelimab-ipdl) Receives the US FDA’s Approval for Cutaneous Squamous Cell Carcinoma (cSCC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
